Abstract
Numerous steatotic livers are discarded for transplantation because of their poor tolerance of ischemia-reperfusion (I/R). The injurious effects of retinol-binding protein 4 (RBP4) in various pathologies are well documented. RBP4 levels are reduced by peroxisome proliferator-activated receptor-γ (PPARγ) agonists. Strategies aimed at increasing PPARγ protect steatotic livers under warm ischemia. Ischemic preconditioning (PC) based on brief periods of I/R protects steatotic liver grafts against I/R injury, but the responsible mechanism is poorly understood. We examined the roles of RBP4 and PPARγ in I/R injury associated with steatotic liver transplantation and the benefits of PC in such situations. We report that RBP4 and PPARγ expression levels in nonsteatotic livers were similar to those found in the sham group. However, reduced RBP4 and increased PPARγ levels were observed in steatotic livers. Treatment with either RBP4 or a PPARγ antagonist was effective only in steatotic livers. PC, which increased RBP4 levels, and RBP4 treatment both reduced PPARγ levels and hepatic injury in steatotic livers. When PPARγ was activated, neither RBP4 treatment nor PC (despite RBP4 induction) protected steatotic livers. In conclusion, steatotic liver grafts are more predisposed to down-regulate RBP4 and overexpress PPARγ. RBP4 treatment and PC, through RBP4 induction, reduced PPARγ levels in steatotic liver grafts, thus protecting them from the PPARγ detrimental effects.
Footnotes
This research was supported by the Ministerio de Sanidad y Consumo (Madrid, Spain) [Project Grant PI060021]; the Ministerio de Ciencia e Innovación (Madrid, Spain) [Project Grant BFU2009-07410]; and the ACC1Ó (Barcelona, Spain) [Project Grant VALTEC08-2-0033]. A.C.-R. received a fellowship from the Agència de Gestió d'Ajuts Universitaris i de Recerca (Barcelona, Spain).
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.110.177691.
-
ABBREVIATIONS:
- I/R
- ischemia-reperfusion
- RBP4
- retinol-binding protein 4
- PPARγ
- peroxisome proliferator-activated receptor-γ
- PC
- ischemic preconditioning
- AMPK
- AMP-activated protein kinase
- Ob
- obese
- Ln
- lean
- UW
- University of Wisconsin
- GW9662
- 2-chloro-5-nitro-N-phenylbenzamide
- rosiglitazone
- (RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione
- AICAR
- aminoimidazole-4-carboxamide ribonucleoside
- AST
- aspartate aminotransferase
- ALT
- alanine aminotransferase
- TR
- transplantation
- PCR
- polymerase chain reaction
- ED50
- median effective dose.
- Received December 3, 2010.
- Accepted April 8, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|